Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 4/2010

Open Access 01-08-2010 | Research article

Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis

Authors: Tomoko Kawabata, Keiichiro Nishida, Koji Takasugi, Hiroko Ogawa, Kenei Sada, Yasutaka Kadota, Junko Inagaki, Satoshi Hirohata, Yoshifumi Ninomiya, Hirofumi Makino

Published in: Arthritis Research & Therapy | Issue 4/2010

Login to get access

Abstract

Introduction

The purpose of this study was to investigate the profile of histone deacetylase (HDAC) expression in the synovial tissue of rheumatoid arthritis (RA) compared with that of normal control and osteoarthritis (OA), and to examine whether there is a link between HDAC activity and synovial inflammation.

Methods

HDAC activity and histone acetyltransferase (HAT) activity were determined in nuclear extracts of total synovial tissue surgically obtained from normal, OA and RA joints. The level of cytoplasmic tumor necrosis factor a (TNFα) fraction was measured by ELISA. Total RNA of synovial tissue was used for RT-PCR of HDAC1-8. In synovial fibroblasts from RA (RASFs), the effects of TNFα on nuclear HDAC activity and class I HDACs (1, 2, 3, 8) mRNA expressions were examined by quantitative real-time PCR. The protein expression and distribution of class I HDACs were examined by Western blotting.

Results

Nuclear HDAC activity was significantly higher in RA than in OA and normal controls and correlated with the amount of cytoplasmic TNFα. The mRNA expression of HDAC1 in RA synovial tissue was higher than in OA and normal controls, and showed positive correlation with TNFα mRNA expression. The protein level of nuclear HDAC1 was higher in RA synovial tissue compared with OA synovial tissue. Stimulation with TNFα significantly increased the nuclear HDAC activity and HDAC1 mRNA expression at 24 hours and HDAC1 protein expression at 48 hours in RASFs.

Conclusions

Our results showed nuclear HDAC activity and expression of HDAC1 were significantly higher in RA than in OA synovial tissues, and they were upregulated by TNFα stimulation in RASFs. These data might provide important clues for the development of specific small molecule HDAC inhibitors.
Appendix
Available only for authorised users
Literature
1.
Mount C, Featherstone J: Rheumatoid arthritis market. Nat Rev Drug Discov. 2005, 4: 11-12. 10.1038/nrd1611.CrossRefPubMed
2.
Huber LC, Stanczyk J, Jungel A, Gay S: Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum. 2007, 56: 3523-3531. 10.1002/art.22948.CrossRefPubMed
3.
Jenuwein T, Allis CD: Translating the histone code. Science. 2001, 293: 1074-1080. 10.1126/science.1063127.CrossRefPubMed
4.
Hassig CA, Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol. 1997, 1: 300-308. 10.1016/S1367-5931(97)80066-X.CrossRefPubMed
5.
Kuo MH, Allis CD: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays. 1998, 20: 615-626. 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H.CrossRefPubMed
6.
Grozinger CM, Schreiber SL: Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002, 9: 3-16. 10.1016/S1074-5521(02)00092-3.CrossRefPubMed
7.
Kruh J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem. 1982, 42: 65-82.PubMed
8.
Chang S, Pikaard CS: Transcript profiling in Arabidopsis reveals complex responses to global inhibition of DNA methylation and histone deacetylation. J Biol Chem. 2005, 280: 796-804.CrossRefPubMed
9.
Mariadason JM, Corner GA, Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000, 60: 4561-4572.PubMed
10.
Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP, Young BD: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer. 2003, 39: 1165-1175. 10.1016/S0959-8049(03)00072-8.CrossRefPubMed
11.
Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, Gannon F: Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene. 2005, 24: 4894-4907. 10.1038/sj.onc.1208662.CrossRefPubMed
12.
Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, Distler JH, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jungel A: Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 2007, 56: 1087-1093. 10.1002/art.22512.CrossRefPubMed
13.
Blanchard F, Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today. 2005, 10: 197-204. 10.1016/S1359-6446(04)03309-4.CrossRefPubMed
14.
Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA. 2002, 99: 2995-3000. 10.1073/pnas.052702999.PubMedCentralCrossRefPubMed
15.
Chung YL, Lee MY, Wang AJ, Yao LF: A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther. 2003, 8: 707-717. 10.1016/S1525-0016(03)00235-1.CrossRefPubMed
16.
Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P: The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005, 11: 1-15. 10.2119/2006-00005.Dinarello.PubMedCentralCrossRefPubMed
17.
Huang N, Katz JP, Martin DR, Wu GD: Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine. 1997, 9: 27-36. 10.1006/cyto.1996.0132.CrossRefPubMed
18.
Bandyopadhyay D, Mishra A, Medrano EE: Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 2004, 64: 7706-7710. 10.1158/0008-5472.CAN-03-3897.CrossRefPubMed
19.
Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H: Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004, 50: 3365-3376. 10.1002/art.20709.CrossRefPubMed
20.
Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002, 8: 718-728.PubMed
21.
Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005, 23: 3912-3922. 10.1200/JCO.2005.02.188.CrossRefPubMed
22.
Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007, 150: 862-872. 10.1038/sj.bjp.0707165.PubMedCentralCrossRefPubMed
23.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed
24.
Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue H, Ohmoto Y, Modlin RL, Makino H: Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 1998, 41: 306-314. 10.1002/1529-0131(199802)41:2<306::AID-ART15>3.0.CO;2-4.CrossRefPubMed
25.
Nakamura K, Hirohata S, Murakami T, Miyoshi T, Demircan K, Oohashi T, Ogawa H, Koten K, Toeda K, Kusachi S, Ninomiya Y, Shiratori Y: Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction. J Biochem. 2004, 136: 439-446. 10.1093/jb/mvh138.CrossRefPubMed
26.
Yamawaki H, Hirohata S, Miyoshi T, Takahashi K, Ogawa H, Shinohata R, Demircan K, Kusachi S, Yamamoto K, Ninomiya Y: Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology. 2009, 19: 83-92. 10.1093/glycob/cwn109.CrossRefPubMed
27.
Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, Apte SS, Ninomiya Y: ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum. 2005, 52: 1451-1460. 10.1002/art.21010.CrossRefPubMed
28.
Hatipoglu OF, Hirohata S, Cilek MZ, Ogawa H, Miyoshi T, Obika M, Demircan K, Shinohata R, Kusachi S, Ninomiya Y: ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells. J Biol Chem. 2009, 284: 16325-16333. 10.1074/jbc.M109.001313.PubMedCentralCrossRefPubMed
29.
30.
Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T: Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002, 37: 458-466. 10.1080/003655202317316105.CrossRefPubMed
31.
Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS: Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003, 111: 539-552.PubMedCentralCrossRefPubMed
32.
Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D, Caprilli R: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest. 2003, 33: 244-248. 10.1046/j.1365-2362.2003.01130.x.CrossRefPubMed
33.
Grabiec AM, Tak PP, Reedquist KA: Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?. Arthritis Res Ther. 2008, 10: 226-10.1186/ar2489.PubMedCentralCrossRefPubMed
34.
Keslacy S, Tliba O, Baidouri H, Amrani Y: Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol Pharmacol. 2007, 71: 609-618. 10.1124/mol.106.030171.CrossRefPubMed
35.
Imre G, Gekeler V, Leja A, Beckers T, Boehm M: Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 2006, 66: 5409-5418. 10.1158/0008-5472.CAN-05-4225.CrossRefPubMed
36.
Yin L, Laevsky G, Giardina C: Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem. 2001, 276: 44641-44646. 10.1074/jbc.M105170200.CrossRefPubMed
37.
Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J. 2002, 21: 2672-2681. 10.1093/emboj/21.11.2672.PubMedCentralCrossRefPubMed
38.
Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S: Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007, 27: 4784-4795. 10.1128/MCB.00494-07.PubMedCentralCrossRefPubMed
39.
Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS: Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem. 2000, 275: 35256-35263. 10.1074/jbc.M003106200.CrossRefPubMed
40.
Higashitsuji H, Higashitsuji H, Masuda T, Liu Y, Itoh K, Fujita J: Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1. J Biol Chem. 2007, 282: 13716-13725. 10.1074/jbc.M609751200.CrossRefPubMed
41.
Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S: Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol. 2009, 36: 1580-1589. 10.3899/jrheum.081115.CrossRefPubMed
42.
Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR: Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA. 1997, 94: 10895-10900. 10.1073/pnas.94.20.10895.PubMedCentralCrossRefPubMed
43.
Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS: Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA. 2002, 99: 10025-10030. 10.1073/pnas.152333199.PubMedCentralCrossRefPubMed
44.
Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, David JR, Bucala R, Morand EF: Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum. 2003, 48: 1881-1889. 10.1002/art.11165.CrossRefPubMed
45.
Kim MM, Yoon SO, Cho YS, Chung AS: Histone deacetylases, HDAC1 and HSIR2, act as a negative regulator of ageing through p53 in human gingival fibroblast. Mech Ageing Dev. 2004, 125: 351-357. 10.1016/j.mad.2004.01.010.CrossRefPubMed
46.
Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, Wu CW: Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem. 2000, 275: 20436-20443. 10.1074/jbc.M000202200.CrossRefPubMed
47.
Taranto E, Xue JR, Lacey D, Hutchinson P, Smith M, Morand EF, Leech M: Detection of the p53 regulator murine double-minute protein 2 in rheumatoid arthritis. J Rheumatol. 2005, 32: 424-429.PubMed
48.
Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP: MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J. 2002, 21: 6236-6245. 10.1093/emboj/cdf616.PubMedCentralCrossRefPubMed
Metadata
Title
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis
Authors
Tomoko Kawabata
Keiichiro Nishida
Koji Takasugi
Hiroko Ogawa
Kenei Sada
Yasutaka Kadota
Junko Inagaki
Satoshi Hirohata
Yoshifumi Ninomiya
Hirofumi Makino
Publication date
01-08-2010
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2010
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3071

Other articles of this Issue 4/2010

Arthritis Research & Therapy 4/2010 Go to the issue

Research article

Effect of duloxetine in patients with fibromyalgia: tiredness subgroups

Research article

Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus

Research article

Exercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial

Research article

Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus

Research article

Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint

Editorial

A new tool for detection of type I interferon activation in systemic lupus erythematosus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits